Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b

Theoretical Biology and Medical Modelling

Volumn 3, Issue , 2006, Pages 1-33

  Marshall, Trevor G ^a   Lee, Robert E ^b   Marshall, Frances E ^c  

^a Autoimmunity Research Foundation   (United States)

^b Black Hawk College   (United States)

^c Los Robles Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CANDESARTAN; CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CCR2; GONADORELIN; IRBESARTAN; LOSARTAN; OLMESARTAN; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SECOSTEROID; TELMISARTAN; VALSARTAN; VITAMIN D RECEPTOR;

ARTICLE; BINDING AFFINITY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; HYDROGEN BOND; HYDROPHOBICITY; IMMUNE SYSTEM; IMMUNOMODULATION; IN VIVO STUDY; MOLECULAR MODEL; MONOCYTE; PHAGOCYTE;

AMINO ACID SEQUENCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; BINDING SITES; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MODELS, MOLECULAR; PPAR GAMMA; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ANGIOTENSIN; RECEPTORS, CALCITRIOL; RECEPTORS, CCR2; RECEPTORS, CHEMOKINE;

EID: 33646267669     PISSN: 17424682     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-3-1     Document Type: Article

References (57)

1. Mann DL, Deswal A: Angiotensin-receptor blockade in acute myocardial infarction - a matter of dose. N Engl J Med 349(20):1963-5. 2003 Nov 13
2. United States Food and Drug Administration: Approval Package for NDA21-286. [http://www.fda.gov/cder/foi/nda/2002/21-286_Benicar_pharmr_P1.pdf]. Pharmacology Review, figures 1.1.1.1,1.1.1.3 and1.1.1.4
3. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T: Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering. J Am Soc Nephrol 2005, 16(12):3631-41.
4. Lewis EJ, Lewis JB: Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol 2003, 7(1):1-8.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
6. Viberti GC, Wheeldon MN: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 2002, 106:672-678.
7. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44(2):362-8. 2004 Jul 21
8. Luno J, Praga M, de Vinuesa SG: The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005, 11(10):1291-300.
9. Waterhouse JC, Marshall TG, Fenter B, Mangin M, Blaney G: High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor - Implications of dysregulated vitamin D for disgnosis and treatment of Chronic Disease. In Vitamin D: New Research Volume 1. Edited by: Stoltz VD. New York: Nova Science Publishers; 2006.
10. Marshall TG, Marshall FE: Sarcoidosis succumbs to antibiotics - implications for autoimmune disease. Autoimmun Rev 2004, 3(4):295-300.
11. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA: Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 93(10):5141-5145. 1996 May 14
12. Cantorna MT, Zhu Y, Froicu M, Wittke A: Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004, 80(6 Suppl):1717S-20S.
13. Mallat Z, Ait-Oufella H, Tedgui A: Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 2005, 16(5):518-24.
14. Yoon JW, Jun HS: Autoimmune destruction of pancreatic Beta cells. Am J Ther 2005, 12(6):580-91.
15. Wittke A, Weaver V, Mahon BD, August A, Cantorna MT: Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J Immunol 173(5):3432-6. 2004 Sep 1
16. Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E: gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab 1997, 82(7):2222-32.
17. Potashnik G, Lunenfeld E, Levitas E, Itskovitz J, Albutiano S, Yankowitz N, Sonin Y, Levy J, Glezerman M, Shany S: The relationship between endogenous oestradiol and vitamin D3 metabolites in serum and follicular fluid during ovarian stimulation for invitro fertilization and embryo transfer. Hum Reprod 1992, 7(10):1357-60.
18. Chatterjee M: Vitamin D and genomic stability. Mutat Res 475(1-2):69-87. 2001 Apr 18
19. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26(5):662-87.
20. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43(5):993-1002.
21. Cabrero A, Laguna JC, Vazquez M: Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 2002, 1:243-8.
22. Genolet R, Wahli W, Michalik L: PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004, 3(4):361-75.
23. Preobrazhensky AA, Dragan S, Kawano T, Gavrilin MA, Gulina IV, Chakravarty L, Kolattukudy PE: Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J Immunol 165(9):5295-303. 2000 Nov 1
24. Tanaka S, Green SR, Quehenberger O: Differential expression of the isoforms for the monocyte chemoattractant protein-1 receptor, CCR2, in monocytes. Biochem Biophys Res Commun 290(1):73-80. 2002 Jan 11
25. Casey PJ, Gilman AG: G protein involvement in receptor-effector coupling. J Biol Chem 263(6):2577-80. 1988 Feb 25
26. AutoDock, Automatic Docking of Flexible Ligands to Macromolecules [http://www.scripps.edu/mb/olson/doc/autodock/]
27. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem 19:1639-1662.
28. Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS: Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 46(1):34-40. 2002 Jan 1
29. Toprakci M, Yelekci K: Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett 15(20):4438-46. 2005 Oct 15
30. Chen K, Adelstein SJ, Kassis AI: Molecular simulation of ligand-binding with DNA: implications for 125I-labeled pharmaceutical design. Int J Radiat Biol 2004, 80(11-12):921-6.
31. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM: Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98(24):13919-24. 2001 Nov 20
32. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D: The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000, 5(1):173-9.
33. Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R, Verstuyf A: Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol Pharmacol 2005, 67(5):1566-73.
34. Scripps Research Institute, Molecular Graphics Laboratory, MGLtools [http://www.scripps.edu/~sanner/software/]
35. The Python Molecular Viewer [http://www.pymol.org]
36. Strader CD, Fong TM, Graziano MP, Tota MR: The family of G-protein-coupled receptors. FASEB J 1995, 9(9):745-54.
37. Shi XF, Liu S, Xiangyu J, Zhang Y, Huang J, Liu S, Liu CQ: Structural analysis of human CCR2b and primate CCR2b by molecular modeling and molecular dynamics simulation. J Mol Model (Online) 2002, 8(7):217-22.
38. Pappu RV, Marshall GR, Ponder JW: A potential smoothing algorithm accurately predicts transmembrane helix packing. Nat Struct Biol 1999, 6(1):50-5.
39. TINKER - Software tools for molecular design [http://dasher.wustl.edu/tinker]
40. Sali A, Blundell TL: Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779-815. 1993 Dec 5
41. MODELLER Program for comparative protein structure modelling by satisfaction of spatial restraints [http://salilab.org/modeller/modeller.html]
42. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96(10):5698-5703. 1999 May 11
43. Martin SS, Boucard AA, Clement M, Escher E, Leduc R, Guillemette G: Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis. J Biol Chem 279(49):51415-23. 2004 Dec 3
44. Goodsell DS, Olson AJ: Automated Docking of Substrates to Proteins by Simulated Annealing. Proteins 1990, 8(3):195-202.
45. Morris GM, Goodsell DS, Huey R, Olson AJ: Distributed Automated Docking of Flexible Ligands to Proteins: Parallel Applications of AutoDock 2.4. J Comput Aided Mol Des 1996, 10(4):293-304.
46. Omdahl JL, Morris HA, May BK: Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002, 22:139-66.
47. Wang J, Cieplak P, Kollman PA: How Well Does a Restrained Electrostatic Potential (RESP) Model Perform in Calcluating Conformational Energies of Organic and Biological Molecules? J Comput Chem 2000, 21:1049-1074.
48. Akira Dobashi's: 3D Pharmaceutical Structure Database. [http://www.pharmis.org/3dpsd/index.htm]. Tokyo University of Pharmacy and Life Sciences
49. Ghemical molecular modelling package [http://www.bioinfor matics.org/ghemical/]
50. Blair JD: SAMBA: Integrating UNIX and Windows. Seattle: SSC Publishing; 1998. ISBN: 1-57831-006-7
51. Acevedo A, Stoynova L, Davis K, Solorzano R, Collins ED: Role of residues 143 and 278 of the human nuclear Vitamin D receptor in the full-length and Delta165-215 deletion mutant. J Steroid Biochem Mol Biol 2004, 89-90(1-5):83-7.
52. Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, Yuan H, Baker DL, Li Z, Bittman R, Parrill A, Tigyi G: Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of PPAR1. J Biol Chem . 2005 Dec 1.
53. Wallace AC, Laskowski RA, Thornton JM: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995, 8(2):127-34.
54. LIGPLOT-Program for automatically plotting protein-ligand interactions [http://www.biochem.ucl.ac.uk/bsm/ligplot/ligplot.html]
55. McDonald IK, Thornton JM: Satisfying Hydrogen Bonding Potential in Proteins. J Mol Biol 238(5):777-93. 1994 May 20
56. HBPLUS-Hydrogen Bond Calculation Program [http:// www.biochem.ucl.ac.uk/bsm/hbplus/home.html]
57. Shaffer PL, McDonnell DP, Gewirth DT: Characterization of transcriptional activation and DNA-binding functions in the hinge region of the vitamin D receptor. Biochemistry 44(7):2678-85. 2005 Feb 22